You are here: Home » Companies » News
Business Standard

SII to start supplying 1st India-made pneumococcal conjugate jab to govt

The Serum Institute of India (SII) will start supplying the first indigenously developed pneumococcal conjugate vaccine to the Centre from Wednesday, sources said on Tuesday

Topics
Serum Institute of India | indian government | Vaccine

Press Trust of India  |  New Delhi 

Photo: Abhishek Waghmare
Serum Institute of India

The (SII) will start supplying the first indigenously developed pneumococcal conjugate to the Centre from Wednesday, sources said on Tuesday.

The acts against potentially fatal pneumococcal infections such as pneumonia, septicaemia and meningitis.

The doses will be sent to government medical stores depots (GMSD) in Kolkata, Mumbai and Karnal on Wednesday.

The SII has to supply 2.4 crore doses of the to the Health Ministry by December 2021. It will be sent to 37 consignees all over India.

The supply order was issued on February 3 in the name of Prakash Kumar Singh, the director of Government and Regulatory Affairs at the Pune-based SII.

The Health Ministry's order was placed within two days of Finance Minister Nirmala Sitharaman announcing in her 2021-22 Union Budget speech that indigenously made pneumococcal vaccines will be rolled out across the country.

Sitharaman had said that this would avert over 50,000 deaths annually.

India's drug regulator had in July last year granted market approval for the Pneumococcal Polysaccharide Conjugate Vaccine, after reviewing data of all the three phases of the clinical trial submitted by the SII.

The trials were carried out by SII in Indian and in Gambia.

According to the health ministry, this vaccine is used for active immunization against invasive disease and pneumonia caused by streptococcus pneumonia in infants.

"This is the first indigenously developed vaccine in the field of pneumonia," an official source had said, adding this would be much more affordable than the ones produced by Pfizer and GlaxoSmithKline.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, April 06 2021. 19:28 IST
RECOMMENDED FOR YOU
.